Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

Concord Biotech Ltd - 543960 - Intimation About Closure Of Inspection Of Ministry Of Health Pharmacy And Poisons Board, Republic Of Kenya At Valthera (Unit II) Of The Company

 In compliance with the Reg. 30 of LODR, we hereby notify that Ministry of Health Pharmacy and Poisons Board, Republic of Kenya had conducted inspection of Unit II (Formulation facility) of the Company, located at Valthera- Dholka (Unit II) in Ahmedabad, Gujarat. the said inspection has been completed successfully, without any adverse remarks and the company has received the certificate of Good Manufacturing practices (GMP) as on today (i.e. 22/02/2024)
22-02-2024
Bigul

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 In Continuation of our letter dated February 09, 2024 regarding audio recording of the unaudited (Standalone and Consolidated) financial results of the company for the Third Quarter and Nine months ended December 31, 2023 , transcripts of the earnings call for the said period enclosed herewith and available on the website of the company at the following link after sending this letter to you, https://www.concordbiotech.com/investors
16-02-2024
Bigul

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be Meeting Investors (Participants) in the enclosed intimation Discussions will be based on publicly available information. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions. This information is submitted to you pursuant to Regulation 30 (6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015. Kindly note that changes may happen due to exigencies on the part of Host / Participants / Company.
13-02-2024
Bigul

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 47 of the SEBI (LODR) Regulations, 2015, Please find enclosed herewith extracts of the standalone and consolidated unaudited financial results for the Third quarter and Nine months ended December 31, 2023 as published in the Financial express in the english language in all editions and gujarati language in Ahmedabad editions. kindly take the same above in your record purpose.
10-02-2024
Bigul

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Pursuant to the provision of Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, and further to our intimation dated January 31, 2024 to the Stock exchanges regarding Earning call in respect of the Unaudited (Standalone and Consolidated) Financial Results of the company for the Third Quarter and Nine Months ended December 31, 2023, we wish to inform that the said Earning Call was held today at 02:00 PM (IST). The audio recording of the conference call has been hosted on the website of the company and link to access the said recording is as follows: - Link :- https://www.concordbiotech.com/public/assets/pdf/q3fy24-earnings-audio-20240209175243.mp3 Kindly take the above on records.
09-02-2024
Bigul

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Pursuant to Regulation 30 of Schedule III Part A of SEBI (LODR) Regulations, 2015, "investors presentation" on the financial results for the Third Quarter and Nine months ended December 31, 2023 is enclosed.
09-02-2024
Bigul

Concord Biotech Ltd - 543960 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E Thursday, February 08, 2024- Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31, 2023

 Dear Sir/ Ma'am, With reference to the intimation of Board meeting submitted on January 30, 2024, we would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Thursday, February 08, 2024, has inter-alia, approved Unaudited Standalone and Consolidated Financial Results for the Third quarter and Nine months ended December 31, 2023. The said results were also reviewed by the Audit Committee of the Company in its meeting held on February 08, 2024. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we enclose herewith the Unaudited Standalone and Consolidated Financial Results of the Company for the Third quarter and Nine months ended December 31, 2023, along with the Limited Review Report of the Statutory auditors
08-02-2024
Bigul

Concord Biotech Ltd - 543960 - Unaudited Standalone And Consolidated Financial Results For The Third Quarter And Nine Months Ended December 31, 2023

 with reference to the intimation of Board meeting submitted on January 30, 2024, we would like inform you that the Board of Directors of the company , at its meeting held today i.e. Thursday, February 08, 2024, has inter-alia approved unaudited standalone and consolidated financial results for the third quarter and nine months ended on December 31, 2023.
08-02-2024
Bigul

Concord Biotech Ltd - 543960 - Intimation About Completion Of Inspection By Brazilian Health Regulatory Agency (ANVISA) At Dholka Facility (Unit I) Of The Company

 In Compliance with the aforesaid regulations, we hereby notify that Brazilian Health Regulatory Agency (ANVISA) has conducted inspection of our Unit 1 (API facility) of the company, located at Trasad Road, Dholka- 382225 in Ahmedabad. Gujarat from Monday, January 29, 2024 to Thursday, February 01, 2024. The said inspection has been completed successfully, without any adverse remarks.
01-02-2024
Bigul

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, read with Para A of Schedule III thereto, We wish to inform you that the Company has arranged Earnings Call with Investor/Analyst (Participants) to discuss the unaudited (Standalone and Consolidated) Financial Results of the Company for the Third quarter and Nine months ended 31 December, 2023, scheduled on Friday, 9th February, 2024 at 02:00 P.M. IST. The Earnings Call invite is enclosed for your records. The conference/Earning Call Invitation is enclosed herewith. Kindly take the same into your records and oblige.
31-01-2024
Next Page
Close

Let's Open Free Demat Account